Validation of a 3D Instrumented Serious Game to Evaluate Upper Limb Impairments in Children With Neuromotor Disorders

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age5-13
SponsorUniversity Hospital, Geneva

About this trial

The goal of this clinical trial is to validate an instrumented 3D serious game to assess upper limb impairments in children with neuromotor disorders. The main questions are:

* Does an instrumented 3D serious game can provide a set of validated upper limb movement features with good reliability, validity and responsiveness ? * Does the instrumented 3D serious game could provide better immersion, adhesion, usability and satisfaction than a "classic" 3D protocol, thanks to the developped environment ?

Researchers will compare children with neuromotor disorders and typically developing children to assess discriminant validity of the new assessement.

Children with neuromotor disorders will have 2 visits to the hospital :

* Visit 1 : children will perform a validated 3D protocol and the instrumented 3D serious game * Visit 2 : children will have a clinical examination and will perform the instrumented 3D serious game

Typically developing children will have one visit to the hospital. They will perform the instrumented 3D serious game.

Eligibility criteria

Qualifiers

Children with NMD

Informed Consent signed by the subject

Aged from 5 to 13 years,

Non-progressive neurological lesions (cerebral palsy, stroke, traumatic brain injury, etc.),

Disqualifiers

Children with neuromotor disorders

inability to follow the procedures of the investigation because of severe cognitive or visual disturbances,

upper limb (UL) disorders that may affect movement (fractures less than 6 months prior to participation, pain (visual analogic score (VAS) score > 0), etc.).

previous UL surgery, and botulinum toxin injections less than three months prior to participation,

Trial design

Treatments tested in this trial

  • instrumented 3D serious game (BE API 3.0)

Treatment groups

40 Participants
are divided into 2 treatment groups

Sponsors and collaborators